logo-loader
viewAIM ImmunoTech Inc.

Full interview: AIM ImmunoTech CEO offers corporate update on lead drug, fundraising efforts

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels offered Proactive an update on the the biotech firm's activities over the past few months. 

Formerly known as Hemispherx Biopharma, Equels says over the past few months the company has changed its name and raised approximately $10 million from the public markets to support its lead drug cancer treatment candidate Ampligen. 

Quick facts: AIM ImmunoTech Inc.

Price: 2.93 USD

NYSE:AIM
Market: NYSE
Market Cap: $24.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read